Tenet Healthcare (THC) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Tenet Healthcare (THC) right now is USPI ambulatory surgery leadership: United Surgical Partners International is the largest ambulatory surgery center platform in the United States, with interests in more than 500 surgery centers and over two dozen surgical hospitals. Revenue (TTM) is ~$21.4 billion. If that keeps playing out, the setup is favourable; the risk to it is hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. No one can predict where THC trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Tenet Healthcare (THC) higher?
1. USPI ambulatory surgery leadership.
United Surgical Partners International is the largest ambulatory surgery center platform in the United States, with interests in more than 500 surgery centers and over two dozen surgical hospitals. USPI grows faster and at higher margins than the hospital base and rides the multi-year shift of procedures from inpatient to outpatient settings. Same-facility surgical revenue and net revenue per case have been growing at healthy rates.
2. Business mix shift toward higher-margin services.
Tenet has sold hospitals and reinvested in USPI, tilting the revenue mix toward the higher-margin ambulatory business. This mix shift, combined with disciplined expense management and acquisitions of new centers, has expanded consolidated EBITDA margins well above historical hospital-operator norms.
3. Deleveraging and improved earnings quality.
Management has prioritized reducing debt, cutting interest expense, and returning capital through buybacks. Sustained deleveraging and EBITDA strength have driven credit-rating upgrades, and lower interest expense has compounded strong earnings-per-share growth over the past two years.
4. Conifer revenue cycle services.
Conifer Health Solutions provides revenue cycle management, patient communications, and value-based care support to hospitals and health systems, including Tenet's own facilities and third-party clients. It is a smaller, steadier services contributor that diversifies Tenet away from pure patient-care revenue.
What could weigh on THC?
Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices.
Where THC trades today
A forecast starts from where the stock actually is. These are THC's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for THC as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a THC forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the THC guide and whether THC is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the THC outlook
The bottom line: what is driving Tenet Healthcare (THC) is USPI ambulatory surgery leadership, with revenue (ttm) at ~$21.4 billion. If that keeps playing out the setup is favourable; the risk is hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. No one can predict the price, so treat any THC forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around THC with Walnut
Use Tenet Healthcare as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Tenet Healthcare (THC)?
+
No one can reliably predict where THC will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Tenet Healthcare higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive THC higher?
+
The main growth drivers are USPI ambulatory surgery leadership; Business mix shift toward higher-margin services; Deleveraging and improved earnings quality. Whether they play out is the real question, not a guaranteed path.
What are the risks to THC?
+
Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices.
Will THC stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Tenet Healthcare's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is THC a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the THC "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.